Author

Kristi Elkins

Observed institutions: Genentech, Leeds Teaching Hospitals NHS Trust, CytomX Therapeutics (United States), University of York, Hull York Medical School

ORCID: 0000-0002-9806-9190

Observed ORCID: 0000-0002-9806-9190

OpenAlex ID: A5047317650

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

2009 · David Dornan, Fiona Bennett, et al. · Blood · 273

Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection

2009 · Andrew G. Polson, Jill Calemine-Fenaux, et al. · Cancer Research · 252

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma

2007 · Andrew G. Polson, Shang-Fan Yu, et al. · Blood · 173

FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2012 · Kristi Elkins, Bing Zheng, et al. · Molecular Cancer Therapeutics · 97

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

2013 · Dongwei Li, Kirsten Achilles Poon, et al. · Molecular Cancer Therapeutics · 85

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

2013 · David S. Shames, Kristi Elkins, et al. · Clinical Cancer Research · 82

Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618

2013 · Yang Xiao, Kristi Elkins, et al. · Neoplasia · 80

In vivoeffects of targeting CD79b with antibodies and antibody-drug conjugates

2009 · Bing Zheng, Reina N. Fuji, et al. · Molecular Cancer Therapeutics · 54

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

2022 · Shweta Singh, Laura Serwer, et al. · Molecular Cancer Therapeutics · 41

Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors

2014 · Weiru Wang, Kristi Elkins, et al. · PLoS ONE · 37

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

2011 · Bart Burington, Peng Yue, et al. · Science Translational Medicine · 37

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

2009 · Andrew G. Polson, Bing Zheng, et al. · Blood · 6

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

2008 · Andrew G. Polson, Fiona L Bennett, et al. · Blood · 6

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

2009 · David Dornan, Bart Burington, et al. · Blood · 1

Pharmacodynamics, Pharmacokinetics, and Tolerability of a B-Cell Specific Antibody-Targeted Chemotherapeutic Agent, Anti-CD79b-MCC-DM1, in Cynomolgus Monkeys

2008 · Marna Williams, Dongwei Li, et al. · Blood · 1

Antibody-Drug Conjugates with Uncleavable Linkers for the Treatment of Non-Hodgkin Lymphoma.

2007 · Andrew G. Polson, Suzanna Clark, et al. · Blood · 1

Data from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

2023 · Dongwei Li, Kirsten Achilles Poon, et al.

Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

2023 · Shweta Singh, Laura Serwer, et al.

Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

2023 · Kristi Elkins, Bing Zheng, et al.

Works count: 54

Citation count: 1,226

H-index: 11

I10-index: 11